Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APMNYSE:DNANASDAQ:TLRYTSE:VBV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.03+11.5%$0.88$0.46▼$7.49$5.59M-0.16613,610 shs129,847 shsDNAGinkgo Bioworks$7.14+2.7%$7.19$5.00▼$23.24$417.63M1.291.45 million shs738,942 shsTLRYTilray$0.41-3.9%$0.49$0.37▼$2.15$411.66M1.9534.78 million shs33.58 million shsVBVVBI VaccinesC$0.00C$3.85▼C$7.60C$308.86MN/A3,637 shs1,300 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group0.00%+1.48%-3.12%+1.01%-81.91%DNAGinkgo Bioworks0.00%-0.43%-1.14%-13.43%-67.08%TLRYTilray0.00%-0.95%-3.71%-35.88%-75.66%VBVVBI Vaccines0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group1.7899 of 5 stars0.05.00.00.03.41.70.6DNAGinkgo Bioworks0.931 of 5 stars0.82.00.00.02.82.51.3TLRYTilray1.4686 of 5 stars3.11.00.00.02.00.01.3VBVVBI VaccinesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/ADNAGinkgo Bioworks 1.67Reduce$5.77-19.23% DownsideTLRYTilray 2.25Hold$1.92368.62% UpsideVBVVBI Vaccines 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APM, DNA, TLRY, and VBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025TLRYTilrayRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/9/2025TLRYTilrayPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K12.76N/AN/A$2.97 per share0.35DNAGinkgo Bioworks$237.42M1.76N/AN/A$21.93 per share0.33TLRYTilray$210.48M1.96N/AN/A$4.14 per share0.10VBVVBI VaccinesC$3.36M0.00N/AN/AC$1.01 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$2.83MN/A0.00∞N/AN/AN/AN/AN/ADNAGinkgo Bioworks-$892.87M-$9.16N/AN/AN/A-298.78%-58.54%-34.24%8/7/2025 (Estimated)TLRYTilray-$244.98M-$1.05N/AN/AN/A-30.95%-4.40%-3.57%7/28/2025 (Estimated)VBVVBI VaccinesN/A-C$0.97N/AN/AN/AN/AN/AN/AN/ALatest APM, DNA, TLRY, and VBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million4/8/2025Q3 2025TLRYTilray-$0.04-$0.10-$0.06-$0.87$213.38 million$185.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/ATLRYTilrayN/AN/AN/AN/AN/AVBVVBI VaccinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum Group0.241.16N/ADNAGinkgo BioworksN/A5.795.79TLRYTilray0.102.541.58VBVVBI Vaccines14.292.642.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%DNAGinkgo Bioworks78.63%TLRYTilray9.35%VBVVBI VaccinesN/AInsider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%DNAGinkgo Bioworks9.72%TLRYTilray0.87%VBVVBI VaccinesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.87 millionNot OptionableDNAGinkgo Bioworks64058.53 million51.89 millionOptionableTLRYTilray2,6501.01 billion929.50 millionOptionableVBVVBI Vaccines2264.08 millionN/ANot OptionableAPM, DNA, TLRY, and VBV HeadlinesRecent News About These CompaniesDecades of research push cytomegalovirus vaccine closer to realityJanuary 7, 2025 | msn.comFive Covid-19 vaccine false theories - debunkedOctober 26, 2024 | bbc.co.ukVBIVQ VBI Vaccines Inc.August 15, 2024 | seekingalpha.comVBI Vaccines Inc. (Nasdaq: VBIV) Rises from the Ashes and is NASDAQ Top Percentage GainerAugust 6, 2024 | investorideas.comVBI Vaccines Starts Restructuring Procedure in CanadaJuly 30, 2024 | marketwatch.comVBI Vaccines secures court protection as it restructures, seeks buyer(s)July 30, 2024 | fiercebiotech.comVBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023April 16, 2024 | msn.comVBI Vaccines sells hepatitis B vaccine candidate, manufacturing digs to partner Brii Biosciences for up to $33 millionFebruary 14, 2024 | fiercepharma.comThe Truth About VaccinesJanuary 6, 2024 | webmd.comVBI Vaccines Inc VBIVOctober 31, 2023 | morningstar.comAccess to new Covid-19 vaccines delayed for Vermonters on MedicaidSeptember 27, 2023 | vtdigger.orgNo, Pfizer COVID-19 vaccine doesn't cause 'VAIDS.' That's not a real condition | Fact checkSeptember 26, 2023 | usatoday.comAvailability of new 2023–2024 COVID-19 vaccine in VirginiaSeptember 26, 2023 | newsleader.comThe Consumer’s Guide to RSV Vaccines for Older AdultsSeptember 24, 2023 | everydayhealth.comUpdated COVID-19 vaccine recommended for everyone; old, young, immunocompromised will benefit mostSeptember 23, 2023 | usatoday.comIs It Safe to Get Multiple Vaccines at the Same Time?September 22, 2023 | everydayhealth.comThe real data behind the new COVID vaccines the White House is pushingSeptember 21, 2023 | nypost.comNew COVID vaccines will be available in RI. Here's how to get one.September 20, 2023 | providencejournal.comCOVID vaccine pill that kills virus before it infects the body could be comingSeptember 15, 2023 | nypost.comInterim results show Brii’s therapeutic HBV vaccine induces immune responseSeptember 8, 2023 | bioworld.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPM, DNA, TLRY, and VBV Company DescriptionsAptorum Group NASDAQ:APM$1.03 +0.11 (+11.52%) As of 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Ginkgo Bioworks NYSE:DNA$7.14 +0.19 (+2.73%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Tilray NASDAQ:TLRY$0.41 -0.02 (-3.92%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.VBI Vaccines TSE:VBVVBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
